Metadata
- Name
- Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT04858529
- Description
- The neoCARHP study was a randomized, open-label, multicenter, phase III, neoadjuvant trial.
This study aimed to compare the efficacy and safety of
docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) with docetaxel/trastuzumab/pertuzumab
(THP) neoadjuvant setting for HER2-positive breast cancer. Patients will be randomized at a
1:1 ratio into TCHP or THP, respectively, and will be treated every 3 weeks before
surgery.The primary endpoint was the percentage of pCR (ypT0/is, ypN0), which was defined as
the absence of any residual invasive cancer in both the breast and axillary lymph nodes. - Data or Study Types
- clinical trial
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2021
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT04858529
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04858529